Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar 19;108(5):1071-8.
doi: 10.1038/bjc.2013.48. Epub 2013 Feb 14.

Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs

R W F van Leeuwen  1 , D H S Brundel, C Neef, T van Gelder, R H J Mathijssen, D M Burger, F G A Jansman
Affiliations

Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs

R W F van Leeuwen et al. Br J Cancer. .

Abstract

Background: Potential drug-drug interactions (PDDIs) in patients with cancer are common, but have not previously been quantified for oral anticancer treatment. We assessed the prevalence and seriousness of potential PDDIs among ambulatory cancer patients on oral anticancer treatment.

Methods: A search was conducted in a computer-based medication prescription system for dispensing oral anticancer drugs to outpatients in three Dutch centres. Potential drug-drug interactions were identified using electronic (Drug Interaction Fact software) and manual screening methods (peer-reviewed reports).

Results: In the 898 patients included in the study, 1359 PDDIs were identified in 426 patients (46%, 95% confidence interval (CI)=42-50%). In 143 patients (16%), a major PDDI was identified. The drug classes most frequently involved in a major PDDI were coumarins and opioids. The majority of cases concerned central nervous system interactions, PDDIs that can cause gastrointestinal toxicity and prolongation of QT intervals. In multivariate analysis, concomitant use of more drugs (odds ratio (OR)=1.66, 95% CI=1.54-1.78, P<0001) and genito-urinary cancer (OR=0.25, 95% CI=0.12-0.52, P<0001) were risk factors.

Conclusion: Potential drug-drug interactions are very common among cancer patients on oral cancer therapy. Physicians and pharmacists should be more aware of these potential interactions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Classification of potential drug–drug interactions (Drug Interaction Facts). aPotential drug-drug interaction.
Figure 2
Figure 2
Prevalence, classification, and mechanism of potential drug interactions. aPotential drug-drug interactions.
See this image and copyright information in PMC

References

    1. Drug Interaction Facts Version 4.0. (2006) Wolters Kluwer Health. Available at: http://www.factsandcomparisons.com (Last consulted on 16 January 2013)
    1. Scientific Advisory Board of the Arizona Center for Education and Research on Therapeutics (CERT) QT Drug ListsAvailable at: http://www.arizonacert.org 2 (Last consulted on 16 January 2013)
    1. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm. 2007;64 (suppl 5:S4–S7. - PubMed
    1. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004;61:380–385. - PubMed
    1. Bourré-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37:1416–1421. - PubMed

Substances